Netherlands Pharmaceuticals & Healthcare Report Q2 2015
Headline Expenditure Projections
- Pharmaceuticals: EUR5.92bn (USD7.93bn) in 2014 to EUR5.85bn (USD7.31bn) in 2015; -1.2% in local currency terms and -7.9% in US dollar terms.
- Healthcare: EUR71.31bn (USD95.56bn) in 2014 to EUR72.55bn (USD90.69bn) in 2015; 1.7% in local currency terms and -5.1% in US dollar terms.
The Netherlands continues to rank in the lower half of BMI's Risk/Reward Index (RRI) for the 15 key Western European markets, ranking 11th in our ratings for Q215. The country has moved up a position from last quarter. At 65.9, its overall RRI score remains only slightly below the regional average of 67.4. While the country offers drugmakers a relatively low-risk operating environment, poor market prospects - due to pressures on pricing and reimbursement and the market's maturity - will continue to weigh down the country's overall standing.
Key Trends And Developments
Dutch electronics company Philips has entered an agreement to acquire US-based medical device maker Volcano for USD1.2bn or USD18 a share, including debt. The offer represents a 57% premium on Volcano's closing price of USD11.49 on December 16. The acquisition aims to tap into the ageing population's need for more complex treatments, and will bolster Philips' line-up of medical imaging devices. The deal is expected to add to Philips' earnings per share by 2017, according to the company's statement. Volcano manufactures imaging catheters, which are used in...
The Netherlands Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.
BMI's Netherlands Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Netherlands pharmaceutical and healthcare industry.
- Benchmark BMI's pharmaceutical and healthcare market forecasts for Netherlands, to test other views - a key input for successful budgeting and strategic business planning in the Dutch pharmaceutical and healthcare market.
- Target business opportunities and risks in the Dutch pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Netherlands.
- Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.
BMI Industry View
An at-a-glance perspective on the latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMIs forecast analysis, and taken together with BMIs political, economic and business environment SWOTs, it gives a complete overview of market climate.
BMI Industry Forecast Scenario
Industry forecasts to end-2019 for all key indicators, supported by explicit assumptions, plus analysis of key downside risks to the main forecasts:
BMIs Pharmaceuticals and Healthcare Risk Reward Index
- Healthcare: Total healthcare expenditure (USDbn), healthcare expenditure (% of GDP), healthcare expenditure per capita (USD), hospital beds, doctors, and birth & mortality rates (all per 000 population).
- Pharmaceutical Market: Drug expenditure in USDbn, % of GDP and per capita (USD).
- Patented Drug Market: Prescription drug sales (USDbn & % of total sales).
- Generic Drug Market: Generic product sales (USDbn), generic sales (% of total sales).
- OTC Drug Market: OTC sales (USDbn & % of total sales).
- Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against USD, government expenditure and external debt.
BMIs Risk Reward Index provides investors (both national and multinational) looking for opportunities in the region with a clear country-comparative assessment of the markets risks and potential rewards. Each of the country markets are scored using a sophisticated model that includes more than 40 industry, economic and demographic data points to provide indices of highest to lowest appeal to investors, with each position explained.
A snapshot of key market characteristics, including total size of the pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape
A focus on government healthcare reforms, epidemiological trends, mergers and acquisitions, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.
Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as analysis of the overall regulatory burden.
The competitive landscape section provides comparative company analyses and index by USD sales and % share of total sales for the total pharmaceutical sector, as well as the OTC, generics and distribution sub-sectors.
Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMIs industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.
*Company profiles are not available for every country. Those reports instead contain information on the current activities of prominent companies operating in the market.
Although the Dutch economy is expected to grow above the eurozone average over 2015 and 2016, the government will most likely continue to target the healthcare sector, resulting in further drug price cuts as it responds to rising healthcare costs from the demands of an increasing aging population. We uphold our view that the Netherlands ' generic and patented drug manufactures will continue to face difficult challenges and that overall market growth will be marginal over the coming years.
BMI Industry View
Pharmaceutical Market Forecast
Table: Pharmaceutical Sales, Historical Data And Forecasts (Netherlands 2010-2018)
Healthcare Market Forecast
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Netherlands 2010-2018)
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Netherlands 2010-2018)
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Netherlands 2010-2018)
Prescription Drug Market Forecast
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Netherlands 2010-2018)
Patented Drug Market Forecast
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Netherlands 2010-2018)
Table: Generics Drug Market Indicators, Historical Data And Forecasts (Netherlands 2010-2018)
OTC Medicine Market Forecast
Table: OTC Medicine Sales Indicators By Category, 2008-2010
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Netherlands 2010-2018)
Pharmaceutical Trade Forecast
Table: Pharmaceutical Trade Data And Forecast (Netherlands 2012-2018)
Table: Pharmaceutical Trade Data And Forecasts local currency (Netherlands 2012-2018)
Other Healthcare Data
Table: Number Of Physicians By Type, 2007-2010
Key Risks To BMI's Forecast Scenario
Table: Netherlands - Economic Activity
Industry Risk Reward Ratings
Western Europe Risk/Reward Ratings
Netherlands Risk/Reward Ratings
Industry Trends And Developments
Table: Key Points Of The Dutch Health Insurance Act, January 1 2006
Healthcare Insurance Developments
Table: Biosimilars Approved In The EU
Research And Development
Intellectual Property Regime
Table: Pharmaceutical Production, 1995-2010 (EUR '000s)
Recent Company Activity
Pharmaceutical Wholesale Sector
Pharmaceutical Retail Sector
Merck & Co
Table: The Netherlands' Population By Age Group, 1990-2020 ('000)
Table: The Netherlands' Population By Age Group, 1990-2020 (% of total)
Table: The Netherlands' Key Population Ratios, 1990-2020
Table: The Netherlands' Rural And Urban Population, 1990-2020
Pharmaceutical Expenditure Forecast Model
Healthcare Expenditure Forecast Model
Notes On Methodology
Risk/Reward Ratings Methodology
Table: Pharmaceutical Risk/Reward Ratings Indicators
This report does not have a list of Companies Mentioned available
This report does not have a press release associated with it